Details for New Drug Application (NDA): 219500
✉ Email this page to a colleague
The generic ingredient in ENBUMYST is bumetanide. There are six drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
Summary for 219500
| Tradename: | ENBUMYST |
| Applicant: | Corstasis Therap |
| Ingredient: | bumetanide |
| Patents: | 3 |
Pharmacology for NDA: 219500
| Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for 219500
Suppliers and Packaging for NDA: 219500
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ENBUMYST | bumetanide | SPRAY;NASAL | 219500 | NDA | Renaissance Lakewood LLC | 49396-0050 | 49396-0050-2 | 12 BLISTER PACK in 1 CARTON (49396-0050-2) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / .1 mL in 1 VIAL, SINGLE-DOSE |
| ENBUMYST | bumetanide | SPRAY;NASAL | 219500 | NDA | Renaissance Lakewood LLC | 49396-0050 | 49396-0050-6 | 6 BLISTER PACK in 1 CARTON (49396-0050-6) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / .1 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;NASAL | Strength | 0.5MG/SPRAY | ||||
| Approval Date: | Sep 12, 2025 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 4, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 4, 2040 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | INTRANASAL BUMETANIDE FOR THE TREATMENT OF EDEMA | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 4, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | INTRANASAL BUMETANIDE FOR THE TREATMENT OF EDEMA | ||||||||
Complete Access Available with Subscription
